References

1. Baehner M, Imhof-Jung S, Kavlie A, Kettenberger H, Klein C, Thomas J, Schaefer W, Stubenrauch K-G, Thomas M. (2015) Bispecific, bivalent anti-VEGF/anti-ANG-2 antibodies. Patent number: US8945552 B2. Assignee: Hoffmann-La Roche Inc.. Priority date: 26/03/2010. Publication date: 03/02/2015.

2. Daly C, Eichten A, Castanaro C, Pasnikowski E, Adler A, Lalani AS, Papadopoulos N, Kyle AH, Minchinton AI, Yancopoulos GD et al.. (2013) Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res, 73 (1): 108-18. [PMID:23149917]

3. Leung DDM, Xu J. (2015) Ang2 antibodies. Patent number: WO2015179166A1. Assignee: Eli Lilly And Company. Priority date: 19/05/2014. Publication date: 26/11/2015.

4. Oliner JD, Min H. (2006) Specific binding agents of human angiopoietin-2. Patent number: US7138370 B2. Assignee: Amgen Inc.. Priority date: 11/10/2001. Publication date: 21/11/2006.

5. Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J et al.. (2016) Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med, 8 (11): 1265-1288. [PMID:27742718]